These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 15529681)
21. [Tick-borne encephalitis is on the increase and high-risk areas are expanding. Are you up-to-date?]. Füessl HS MMW Fortschr Med; 2007 Feb; 149(5):28-9. PubMed ID: 17615727 [No Abstract] [Full Text] [Related]
22. Tick-borne encephalitis--still a serious disease? Kaiser R Wien Med Wochenschr; 2012 Jun; 162(11-12):229. PubMed ID: 22695812 [No Abstract] [Full Text] [Related]
23. Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination. Kleiter I; Jilg W; Bogdahn U; Steinbrecher A Infection; 2007 Feb; 35(1):26-9. PubMed ID: 17297586 [TBL] [Abstract][Full Text] [Related]
24. Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children. Wittermann C; Petri E; Zent O Vaccine; 2009 Mar; 27(10):1585-8. PubMed ID: 19162115 [TBL] [Abstract][Full Text] [Related]
25. [Vaccination with Encepur of children using the rapid scheme produces stable and long-term prevention of tick-borne meningoencephalitis]. Kinderkrankenschwester; 2007 Jun; 26(6):245-6. PubMed ID: 17626570 [No Abstract] [Full Text] [Related]
26. Field effectiveness of vaccination against tick-borne encephalitis. Heinz FX; Holzmann H; Essl A; Kundi M Vaccine; 2007 Oct; 25(43):7559-67. PubMed ID: 17869389 [TBL] [Abstract][Full Text] [Related]
27. [New TBE vaccine formulations--free of proteineous stabilizer and preservatives. Overview of clinical studies and first year post-marketing experience]. Zent O; Wittermann Ch; Banzhoff A; Plentz A; Jilg W MMW Fortschr Med; 2004 Jan; 146(3-4):43. PubMed ID: 15035448 [No Abstract] [Full Text] [Related]
28. TBE infection in an incomplete immunized person at-risk who lives in a high-endemic area--impact on current recommendations for immunization of high-risk groups. Plísek S; Honegr K; Beran J Vaccine; 2008 Jan; 26(3):301-4. PubMed ID: 18082914 [TBL] [Abstract][Full Text] [Related]
29. [Study of the reactivity and immunogenicity of FSME-IMMUN vaccine against tick-borne meningoencephalitis]. Borcić B; Majerus-Misić L; Raos B; Punda V; Bujić N; Toth D Lijec Vjesn; 1984 Oct; 106(10):425-8. PubMed ID: 6503595 [No Abstract] [Full Text] [Related]
30. A tick-borne encephalitis vaccine without human serum albumin as stabilizer. Bröker M; Zent O Vaccine; 2005 Dec; 23(50):5699. PubMed ID: 16226355 [No Abstract] [Full Text] [Related]
31. [Active immunization against tick-borne encephalitis in the elderly]. Biró J; Regius O Z Gerontol; 1985; 18(6):337-9. PubMed ID: 3879415 [TBL] [Abstract][Full Text] [Related]